March 05, 2015 3:14 PM ET

Biotechnology

Company Overview of Infinity Pharmaceuticals, Inc.

Company Overview

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to people with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies and inflammatory diseases. The company is conducting DUOTM, a randomized, monotherapy Phase 3 study of IPI-145 in patients with relapsed/refractory chronic lymphocytic leukemia; an ongoing Phase 1 dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignan...

780 Memorial Drive

Cambridge, MA 02139

United States

195 Employees

Phone:

617-453-1000

Fax:

617-453-1001

Key Executives for Infinity Pharmaceuticals, Inc.

Chairman of The Board, Chief Executive Officer and President
Age: 54
Total Annual Compensation: $552.0K
Chief Financial Officer, Chief Business Officer, Executive Vice President, Treasurer and Secretary
Age: 48
Total Annual Compensation: $378.8K
President of Research & Development
Age: 59
Total Annual Compensation: $465.8K
Chief Scientific Officer and Executive Vice President
Age: 51
Total Annual Compensation: $366.4K
Compensation as of Fiscal Year 2013.

Infinity Pharmaceuticals, Inc. Key Developments

Infinity Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Twelve Months Ended December 31, 2014; Announces Update on duvelisib (IPI-145); Provides Earnings Guidance for the Full Year 2015

Infinity Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and twelve months ended December 31, 2014. For the quarter, the company reported loss from operations was $39,108,000 compared with $33,084,000 for the same period last year. Net loss was $40,343,000 or $0.83 basic and diluted per share compared with $32,925,000 or $0.68 basic and diluted per share for the same period last year. Collaboration revenue was $4,356,000. For the twelve months, the company reported loss from operations was $7,923,000 compared with $127,676,000 for the same period last year. Net loss was $17,416,000 or $0.36 basic and diluted per share compared with $126,780,000 or $2.64 basic and diluted per share for the same period last year. Revenue during 2014 was $165 million, which was composed of a onetime license fee of $159.1 million associated with the strategic collaboration with AbbVie and $5.9 million in R&D services. The company also announced ongoing progress with duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Infinity anticipates that it will report topline data from DYNAMOTM, a Phase 2 study of duvelisib in patients with refractory indolent non-Hodgkin lymphoma (iNHL), in the second half of 2015 following the completion of patient enrollment in the first half of the year. Infinity also expects to complete enrollment of DUOTM, a Phase 3 study of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), in the second half of 2015. Additionally, Infinity anticipates that three company-sponsored clinical studies of duvelisib will be initiated in 2015, including the first clinical study of duvelisib in combination with venetoclax (ABT-199). For 2015, the company expects revenue to range from $105 million to $125 million based upon the anticipation of the $130 million milestone payment from AbbVie associated with the completion of enrollment for the first to occur of either DYNAMO or DUO. The company also expects net loss for 2015 to range from $190 million to $210 million.

Infinity Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 03:35 PM

Infinity Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 03:35 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Lawrence E. Bloch, Chief Financial Officer, Chief Business Officer, Principal Accounting Officer, Executive Vice President, Treasurer and Secretary.

Infinity Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 24, 2015

Infinity Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 24, 2015

Similar Private Companies By Industry

Company Name Region
Epigenomics, Inc. United States
Protein Pathways, Inc. United States
CLINIQA Corporation United States
QHP Royalty Sub, LLC United States
TMune Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 11, 2014
Infinity Pharmaceuticals Inc., Worldwide Rights To IPI-940
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Infinity Pharmaceuticals, Inc., please visit www.infi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.